FDA Approves New Anti-Obesity Drug
Contrave, a combination of naltrexone and buproprion, has been approved for long-term weight loss management in overweight and obese adults.
SUBSCRIBE: Print / eNewsletter
Contrave, a combination of naltrexone and buproprion, has been approved for long-term weight loss management in overweight and obese adults.
Results from two large cohorts indicated that increasing blood pressure levels were associated with an increased risk for developing kidney cancer among both men and women.
Ambulatory blood pressure monitoring is a useful prognosis tool to differentiate between true and white coat resistant hypertension, according to a study published online March 28 in Hypertension.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.